SVWAG
NBIX icon

Sound View Wealth Advisors Group’s Neurocrine Biosciences NBIX Stock Holding History

Sound View Wealth Advisors Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
6,372
+958
+18% +$142K 0.07% 182
2026
Q1 		$713K Buy
5,414
+171
+3% +$22.7K 0.05% 233
2025
Q4 		$744K Buy
5,243
+27
+0.5% +$3.91K 0.05% 225
2025
Q3 		$732K Buy
5,216
+116
+2% +$15.7K 0.05% 231
2025
Q2 		$641K Buy
5,100
+190
+4% +$21.8K 0.05% 240
2025
Q1 		$543K Sell
4,910
-26
-0.5% -$3.29K 0.04% 244
2024
Q4 		$674K Buy
4,936
+652
+15% +$80.6K 0.05% 228
2024
Q3 		$494K Buy
4,284
+823
+24% +$113K 0.04% 255
2024
Q2 		$476K Sell
3,461
-314
-8% -$43.1K 0.05% 241
2024
Q1 		$521K Sell
3,775
-407
-10% -$55.6K 0.06% 231
2023
Q4 		$551K Sell
4,182
-352
-8% -$40.5K 0.06% 222
2023
Q3 		$510K Buy
4,534
+515
+13% +$54.2K 0.06% 216
2023
Q2 		$379K Buy
4,019
+515
+15% +$50.3K 0.05% 258
2023
Q1 		$355K Sell
3,504
-678
-16% -$70.6K 0.05% 264
2022
Q4 		$551K Buy
4,182
+2,119
+103% +$248K 0.06% 222
2022
Q3 		$219K Buy
+2,063
New +$209K 0.05% 248

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sound View Wealth Advisors Group's NBIX Position: Q2 2026 in Review

Sound View Wealth Advisors Group increased its Neurocrine Biosciences (NBIX) stake by 18% in Q2 2026, buying an estimated $142K and bringing the position to 6,372 shares worth $1.07M. The position accounts for 0.07% of the portfolio, ranked #182.

Sound View Wealth Advisors Group first reported a position in NBIX in Q3 2022 and has held it in 16 quarters since. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Sound View Wealth Advisors Group held 6,372 shares of Neurocrine Biosciences worth $1.07M as of Q2 2026.
  • Sound View Wealth Advisors Group bought 958 Neurocrine Biosciences shares in Q2 2026, an estimated $142K.
  • Neurocrine Biosciences made up 0.07% of Sound View Wealth Advisors Group's portfolio in Q2 2026, its #182 holding.
  • Sound View Wealth Advisors Group first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 16 quarters since.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sound View Wealth Advisors Group's 13F filing for Q2 2026, filed 11 Aug 2026.